Björn Redfors et al. JACEP 2017;j.jacep

Slides:

Advertisements

Similar presentations

CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease.

Advertisements

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Oana Dickinson et al. JACEP 2016;2:

Prakash Harikrishnan et al. JACEP 2015;1:

Prakash Harikrishnan et al. JACEP 2015;1:

Nat. Rev. Cardiol. doi: /nrcardio

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Noriko Kikuchi et al. JACEP 2016;2:

Tom F. Brouwer et al. JACEP 2016;2:

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

Takekuni Hayashi et al. JACEP 2016;2:27-35

Endothelial Dysfunction in Patients With Lone AF and AF Patients With Comorbidities Compared With That in Controls Comparisons are shown among control.

Masatoshi Yamazaki et al. JACEP 2015;1:

Waddah Maskoun et al. JACEP 2016;2:

Konstantinos C. Siontis et al. JACEP 2016;2:

Kenshi Hayashi et al. JACEP 2016;2:

Tom F. Brouwer et al. JACEP 2016;2:89-96

Masatoshi Yamazaki et al. JACEP 2015;1:

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Tom F. Brouwer et al. JACEP 2016;2:

Tom F. Brouwer et al. JACEP 2016;2:

Identifying High-Risk AF Patients

David F. Katz et al. JACEP 2016;j.jacep

Pablo B. Nery et al. JACEP 2016;2:

Michael G. Klein et al. JACEP 2016;2:

Junaid A.B. Zaman et al. JACEP 2017;3:

Muhammad Shahreyar et al. JACEP 2016;j.jacep

Junjie Zhang et al. JACEP 2017;3:

Stavros Stavrakis et al. JACEP 2015;1:1-13

Prakash Harikrishnan et al. JACEP 2015;1:

Peter F. Aziz et al. JACEP 2015;1:62-70

Michael G. Klein et al. JACEP 2016;j.jacep

Mohit K. Turagam et al. JACEP 2017;3:

Eran Leshem et al. JACEP 2018;j.jacep

Moussa Mansour et al. JACEP 2017;3:

Mu Qin et al. JACEP 2017;j.jacep

Mintu P. Turakhia et al. JACEP 2016;2:

Leonard M. Rademakers et al. JACEP 2016;2:

Prakash Harikrishnan et al. JACEP 2015;1:

Mitsunori Maruyama et al. JACEP 2017;3:

Philippe Taghji et al. JACEP 2017;j.jacep

Vivek Y. Reddy et al. JACEP 2016;2:

Yoshitaka Kimura et al. JACEP 2016;2:

Emilce Trucco et al. JACEP 2018;j.jacep

Vittorio Calzolari et al. JACEP 2017;3:

Junjie Zhang et al. JACEP 2017;3:

Kenshi Hayashi et al. JACEP 2016;2:

David F. Katz et al. JACEP 2017;3:20-28

Björn Redfors et al. JACEP 2017;j.jacep

Masatoshi Yamazaki et al. JACEP 2015;1:

Moussa Mansour et al. JACEP 2016;j.jacep

5 Good Minutes on Atrial Fibrillation-related Stroke

Anna Björkenheim et al. JACEP 2017;j.jacep

Vittorio Calzolari et al. JACEP 2017;3:

Mintu P. Turakhia et al. JACEP 2016;2:

Emilce Trucco et al. JACEP 2018;j.jacep

K.R. Julian Chun et al. JACEP 2017;3:

Björn Redfors et al. JACEP 2017;j.jacep

Bernard Lim et al. JACEP 2016;2:

Adam B. Greenbaum et al. JACEP 2015;1:

Eran Leshem et al. JACEP 2018;j.jacep

Jordan S. Leyton-Mange et al. JACEP 2017;j.jacep

Jose C. Pachon M. et al. JACEP 2015;1:

Miyako Igarashi et al. JACEP 2018;4:

Davide Capodanno et al. JCIN 2009;2:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Maxime Berthelot-Richer et al. JIMG 2016;9:

Maria R. Costanzo et al. JCHF 2016;4:

Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Björn Redfors et al. JACEP 2017;j.jacep.2017.04.024 Relationship Between Yearly Incidence of Ischemic Stroke and Risk Scores in Patients With Contraindication to OAC (A) Yearly stroke rates by CHADS score for the study cohort of OAC-naive patients with contraindication to OAC (n = 43,248; blue). Also presented are expected adjusted yearly stroke rates, by CHA2DS2 score, for a general population of patients with AF (as presented in current guidelines, red). † Adjusted stroke rates in the general population are based on data from Gage et al. (3,14). (B) Yearly stroke rates by CHA2DS2-VASc score for the study cohort of OAC-naive patients with contraindication to OAC (n = 43,248; blue). Also presented are expected adjusted yearly stroke rates, by CHA2DS2 score, for a general population of patients with AF (as presented in current guidelines, red). ‡Adjusted stroke rates in the general population are based on data from Lip et al. (3,13). Abbreviations as in Figure 1. Björn Redfors et al. JACEP 2017;j.jacep.2017.04.024 2017 American College of Cardiology Foundation